company background image
NHWK

NightHawk Biosciences NYSEAM:NHWK Stock Report

Last Price

US$1.11

Market Cap

US$28.5m

7D

-5.9%

1Y

-59.8%

Updated

07 Feb, 2023

Data

Company Financials +

NightHawk Biosciences, Inc.

NYSEAM:NHWK Stock Report

Mkt Cap: US$28.5m

NHWK Stock Overview

NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines.

NHWK fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

NightHawk Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NightHawk Biosciences
Historical stock prices
Current Share PriceUS$1.11
52 Week HighUS$3.42
52 Week LowUS$0.75
Beta0.59
1 Month Change11.36%
3 Month Change-26.97%
1 Year Change-59.78%
3 Year Change-35.01%
5 Year Change-94.46%
Change since IPO-99.83%

Recent News & Updates

Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Dec 28
Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Recent updates

Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Dec 28
Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Sep 02
Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics names Anthony Manning as chief scientific advisor

May 10

Heat Biologics EPS misses by $0.01, misses on revenue

May 05

We're Hopeful That Heat Biologics (NASDAQ:HTBX) Will Use Its Cash Wisely

Apr 30
We're Hopeful That Heat Biologics (NASDAQ:HTBX) Will Use Its Cash Wisely

Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years

Mar 07
Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Jan 13
Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics signs a licensing agreement; Appoints new CFO

Jan 06

Heat Biologics soars 14% on completion of ZVX-60 vaccine cell line for COVID-19

Dec 16

Introducing Heat Biologics (NASDAQ:HTBX), The Stock That Zoomed 124% In The Last Year

Nov 20
Introducing Heat Biologics (NASDAQ:HTBX), The Stock That Zoomed 124% In The Last Year

Heat Biologics Provides Update, And Other News: The Good, Bad And Ugly Of Biopharma

Nov 02

Shareholder Returns

NHWKUS BiotechsUS Market
7D-5.9%-0.8%0.9%
1Y-59.8%3.9%-10.9%

Return vs Industry: NHWK underperformed the US Biotechs industry which returned 3.9% over the past year.

Return vs Market: NHWK underperformed the US Market which returned -10.9% over the past year.

Price Volatility

Is NHWK's price volatile compared to industry and market?
NHWK volatility
NHWK Average Weekly Movement10.0%
Biotechs Industry Average Movement12.0%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: NHWK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: NHWK's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200849Jeff Wolfhttps://www.nighthawkbio.com

NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company’s therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product.

NightHawk Biosciences, Inc. Fundamentals Summary

How do NightHawk Biosciences's earnings and revenue compare to its market cap?
NHWK fundamental statistics
Market CapUS$28.48m
Earnings (TTM)-US$44.85m
Revenue (TTM)US$6.92m

4.1x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NHWK income statement (TTM)
RevenueUS$6.92m
Cost of RevenueUS$28.70m
Gross Profit-US$21.78m
Other ExpensesUS$23.06m
Earnings-US$44.85m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.75
Gross Margin-314.98%
Net Profit Margin-648.41%
Debt/Equity Ratio0%

How did NHWK perform over the long term?

See historical performance and comparison